Condition: Primary Immunodeficiency (PID) · Congenital Bone Marrow Failure Syndromes · Inherited Metabolic Disorders (IMD) · Sponsor: Paul Szabolcs
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.
This description comes directly from the study's public registry record.
Paul Szabolcs, MD · 412-692-5427 · paul.szabolcs@chp.edu
Shawna McIntyre, RN · 412-692-5552 · mcintyresm@upmc.edu
Always discuss trial participation with your own doctor first.
| UPMC Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04528355